

Lipid-Lowering Treatment Selector

Charts revised July 2018. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
Stating	Atorvastatin	1	1	↑490%	↓43%	↓37%	\downarrow	\leftrightarrow	1	1								
	Fluvastatin	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	1	\leftrightarrow	1	1									
	Lovastatin	1	1	1	↓	1	1	\leftrightarrow	1	1								
	Pitavastatin	↑31%	\leftrightarrow	\leftrightarrow	↓11%	\leftrightarrow	1	1										
	Pravastatin	\leftrightarrow	↑81%	\leftrightarrow	↓44%	1	\leftrightarrow	1	1									
	Rosuvastatin	↑213%	↑48%	↑107%	\leftrightarrow	↑ 38%	↑ 38%											
	Simvastatin	1	1	1	↓68%	1	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow		\leftrightarrow	\leftrightarrow	1	1
Fihrates	Bezafibrate	\leftrightarrow																
	Clofibrate	\leftrightarrow	↑ 11	\leftrightarrow	\leftrightarrow	↑ 11												
	Fenofibrate	\leftrightarrow																
	Gemfibrozil	↓	↓	↓41%	\leftrightarrow	\leftrightarrow	\leftrightarrow	+	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow		\leftrightarrow		\leftrightarrow	\leftrightarrow	\leftrightarrow
	Ezetimibe	1	\leftrightarrow															

Colour Legend

No clinically significant interaction expected.

These drugs should not be coadministered.

Potential interaction which may require a dosage adjustment or close monitoring.

Potential interaction predicted to be of weak intensity. No a priori dosage adjustment is recommended.

Text Legend

Potential increased exposure of the lipid-lowering drug

Potential increased exposure of HIV drug

Potential decreased exposure of the lipid-lowering drug

No significant effect

Numbers refer to increased or decreased AUC of the lipid-lowering drug as observed in drug-drug interaction studies.